Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale
The Global Malaria Programme has developed a presentation to support the dissemination, adoption and implementation of this policy guidance by national malaria control programmes.
The aim of this policy brief is to disseminate the new WHO recommendations on G6PD testing to ensure safe administration of primaquine for preventing relapse of P. vivax and P. ovale malaria. It offers national malaria control programmes guiding principles and practical advice on:
- classification and testing of G6PD deficiency, highlighting the differences between males and females;
- a diagnostic and treatment algorithm for qualitative point-of-care G6PD testing and anti-relapse treatment with primaquine;
- tables for dosing primaquine and information on the sourcing of quality-assured primaquine;
- checklists for counselling patients, recognizing the symptoms of acute haemolytic anaemia and managing side-effects;
- risk–benefit assessments before administering primaquine without G6PD testing, including considerations for testing in specific countries and geographical areas;
- quantitative and qualitative G6PD tests and the preferred product characteristics of qualitative tests for use at points of care;
- planning and conducting G6PD testing at country level.